Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening.

ABSTRACT:

Background and aims

Multitarget stool DNA (MT-sDNA) testing is now approved by the U.S. Food and Drug Administration for average-risk colorectal cancer screening. Trials leading to its approval used blinded colonoscopy as the reference standard. In the postapproval screen setting, the clinical performance and impact of MT-sDNA testing on unblinded colonoscopy has not been described. We measured the impact that knowledge of a positive MT-sDNA test result has on colonoscopy yield and quality.

Methods

The unblinded group comprised all patients with positive MT-sDNA results on screening from September 1, 2014 to September 30, 2015 at a single tertiary center. Off-label test patients were excluded. The blinded group included all MT-sDNA-positive participants in a preapproval scre

SUBMITTER: Johnson DH 

PROVIDER: S-EPMC10653981 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature